Waking up and seeing a Tweet from @OWCPharma that said NEWS — I just knew it was going to be a beautiful day. I just wanted to highlight some of the key things I read from the annual letter.
First, Mordechai points out the “Key to OWCP’s success is its management team” and proceeds to talk about each individual. (Most, if not all, shareholders agree with that statement too.) Mr. Bignitz ends this section by saying, “Our team’s common objective is to enable the Company to reach the goals and objectives it has outlined for 2017 and future years.”
First, our desire to bring Israel cannabis science to U.S. state-licensed businesses and to Europe, Canada and South America.
Longer-term, OWCP’s objective is to obtain approvals for cannabinoid-based drugs in North America and Europe, including trials under U.S. Food and Drug Administration (“FDA”) protocols. Upon receipt of regulatory approval, which we are actively pursuing, our cannabinoid-based drugs would be available through traditional pharmaceutical distribution channels, including pharmacies to treat a wide variety of medical conditions.
The effective delivery of cannabinoid-based drugs requires optimal delivery systems. We are furthering the development of our proprietary, cannabinoid-enriched sublingual tablet for the administration of medical cannabis, which we anticipate using for future trials for multiple myeloma, Post-Traumatic Stress Disorder (“PTSD”), and fibromyalgia.
OWCP is hopeful that the psoriasis cream will be launched in the U.S. and European markets and we anticipate market readiness and the start of marketing efforts during Q2 – 2017 on a state to state basis and subject to state regulations.
Multiple myeloma is a cancer of plasma cells in bone marrow, and accounts for approximately two percent of all cancer deaths but is highly fatal, with median survival rate of only 3 years.
The results of our in-vitro testing indicated that specific formulations of the cannabinoids CBD and THC decreased the survival of multiple myeloma cells in a concentration-dependent manner, and resulted in a 100 percent malignant cell death in 60 percent of the infected mice.
With the success of its in-vitro mice study, OWCP has determined to proceed with a pre-clinical, Institutional Review Board (IRB) approved protocol on mice to duplicate those results. It is hopeful that these further studies will provide the scientific justification for OWCP to proceed with human trials.
OWCP’s sublingual tablet was developed to increase the bioavailability of the cannabinoids and provide an optimal administration method for cannabinoid-based medicine to patients. It also facilitates the ability to provide accurate and consistent dosing.
The Company’s proprietary technology provides for the ingestion of various dosages of medical cannabis through a sublingual delivery mechanism, which enables the cannabinoids to be absorbed directly into the patient’s blood through oral epithelial tissue.
The sublingual tablet also enables physicians to safely and accurately monitor the dosage and treatment of each patient, something impossible to accomplish for patients who are obtaining cannabis-based medicine by smoking, vaping, or by ingesting extracts or edible products.
The Company’s longer-term objectives include the commencement of clinical trials using its proprietary sublingual tablet as the basis for cannabinoid-based drug trials for multiple myeloma, Post-Traumatic Stress Disorder (PTSD), and fibromyalgia.
I’ve pointed out in our Year End Recap that Jeffrey Friedland is a huge asset. Quite frankly, I’m a fan of Mr. Friedland. He’s all over the Medical Marijuana industry events.
Mr. Friedland has been featured or quoted in numerous publications including the Wall Street Journal, Reuters, the New York Times, Bloomberg Television, USA Today, VersloZinios (Lithuania), Vercernji (Croatia), International Business Times, the South China Morning Post, the Guam Daily Post, the Forward, the Jewish Week, Quartz, the Jakarta Globe, Israel Daily Television, BreitBart, NBC.com and Forbes.
He is also the CEO of Intiva Inc., a platform company active in the global cannabis industry in the United States and Canada. In 2014, INTIVA was an initial investor in OWC Pharmaceutical Research.
OWCP’s Action Items for 2017:
- During the second quarter of 2017 OWCP intends to initiate its U.S marketing program for its Psoriasis Topical Cream. At the same time, we intend to begin investigating the applicability of topical cream for other skin conditions and disorders.
- OWCP intends to proceed with the advancement of our cannabis-based treatment for multiple myeloma, with the objective of proceeding with additional studies.
- OWCP intends to evaluate the launch of one or more studies to determine the applicability of cannabinoid-based pharmaceuticals for other medical conditions and disorders, such as fibromyalgia and migraines.
This is all very exciting. Nothing here is necessarily sending OWCP to $5.00 a share today (even though they should already have a Market Value around that point, but “whatever”.) The point of this Annual Letter is that OWCP accomplished their goals in 2016 and are going after (and making good progress towards) their 2017 goals — which is to start distributing quality, Cannabis-based drugs to Europe and the USA.
It’s going to be a fun year, folks.